Roivant Sciences Ltd. (ROIV) Stock Price & Analysis
Roivant Sciences Ltd. (ROIV) rose 1.97% to USD 29.05 as of June 9, 2026 at 23:49 UTC, according to Nexqual real-time market data.
ROIV last closed at USD 28.49; the session ranged USD 28.31–29.3 on volume of 3,459,006 shares. Market capitalization is $20.89B, with a 52-week range of USD 10.71–32.79 (NMS). Source: Nexqual, June 9, 2026 at 23:49 UTC.
Key Statistics (as of June 9, 2026 at 23:49 UTC)
| Price | USD 29.05 |
|---|---|
| Change | ▲ 1.97% (up) |
| Previous Close | USD 28.49 |
| Open | USD 28.99 |
| Day Range | USD 28.31 – 29.3 |
| 52-Week Range | USD 10.71 – 32.79 |
| Volume | 3,459,006 shares |
| Market Cap | $20.89B |
| Exchange | NMS |
Technical Analysis (ROIV)
Nexqual's technical model rates ROIV "NEUTRAL" based on 3 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 23:49 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.76 (neutral) |
| vs SMA50 | Above (USD 28.79) |
| MACD | 0.02 (positive) |
Analyst Ratings (ROIV)
Wall Street analysts rate ROIV "Strong Buy" based on 12 analysts, with a mean price target of USD 39.04 (range USD 31.5–45), per Nexqual as of June 9, 2026 at 23:49 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 39.04 |
| High Target | USD 45 |
| Low Target | USD 31.5 |
| Buy / Hold / Sell | 12 / 1 / 0 |
Earnings (ROIV)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -0.36 |
| Revenue Estimate | $2.37M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.32 vs est -0.35 ▲ beat |
| 2025-12-31 | USD -0.24 vs est -0.31 ▲ beat |
| 2025-09-30 | USD -0.28 vs est -0.3 ▲ beat |
| 2025-06-30 | USD -0.25 vs est -0.23 ▼ miss |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Financials & Fundamentals (ROIV)
| Total Revenue | $8.26M |
|---|---|
| Revenue Growth (YoY) | -66.70% |
| Gross Margin | +0.00% |
| Operating Margin | -14675.08% |
| Profit Margin | +0.00% |
| ROE | -7.59% |
| Debt / Equity | 2.03 |
| Current Ratio | 18.37 |
| Total Cash | $4.29B |
| Total Debt | $107.44M |
| Free Cash Flow | $-1.09B |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Financial Health Score (ROIV)
Nexqual rates Roivant Sciences Ltd.'s overall financial health "Weak" across five dimensions, as of June 9, 2026 at 23:49 UTC.
| Growth | Critical — Revenue -72% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $4.29B cash vs $107M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$1.09B, burning cash |
| Efficiency | Critical — ROE -8%, ROA -14.4% |
Ownership (ROIV)
| Insider Ownership | +23.39% |
|---|---|
| Institutional Ownership | +75.84% |
| Shares Outstanding | 719.27M |
| Float | 545.51M |
| Short % of Float | +5.02% |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Leadership (ROIV)
Roivant Sciences Ltd. is led by Matthew Gline (age 41), CEO & Director, per Nexqual as of June 9, 2026 at 23:49 UTC.
| CEO & Director | Matthew Gline (age 41) |
|---|---|
| President & CEO of Immunovant | Eric Venker M.D., Pharm.D. (age 38) |
| President, Chief Investment Officer & Director | Mayukh Sukhatme (age 49) |
| Chief Financial Officer | Richard Pulik (age 45) |
| President & Vant Chair | Frank M. Torti (age 46) |
Major Backers & Investors (ROIV)
Notable institutional backers of Roivant Sciences Ltd. include FMR, LLC, Morgan Stanley, Fidelity, according to Nexqual as of June 9, 2026 at 23:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 10.84% |
| Morgan Stanley | 7.97% |
| Fidelity | 4.75% |
| QVT Financial LP | 3.5% |
| UBS Group AG | 3.14% |
| Adage Capital Partners GP L.L.C. | 1.78% |
| Goldman Sachs | 1.54% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 10.72% |
| BlackRock | 8.27% |
| State Street | 2.25% |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
From Roivant Sciences Ltd.'s Latest SEC 10-K Filing (filed 2026-05-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
- The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases.
- In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IMVT | Immunovant, Inc. | USD 31.61 | ▲ 1.61% |
| BBIO | BridgeBio Pharma, Inc. | USD 67.68 | ▲ 0.1% |
| PCVX | Vaxcyte, Inc. | USD 46.88 | ▼ 1.01% |
| LEGN | Legend Biotech Corporation | USD 33.49 | ▲ 2.67% |
| RVMD | Revolution Medicines, Inc. | USD 149.55 | ▲ 0.21% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:49 UTC. This page is informational and not investment advice.